Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate

OBJECTIVES: Methotrexate is considered to be first-line therapy for rheumatoid arthritis (RA). However, a substantial proportion of treated patients do not achieve the desired goals of therapy. This analysis aimed to identify predictors of insufficient response to methotrexate in patients with early...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Rheum Dis
Hlavní autoři: Smolen, Josef S, van Vollenhoven, Ronald F, Florentinus, Stefan, Chen, Su, Suboticki, Jessica L, Kavanaugh, Arthur
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2018
Témata:
Clinical and Epidemiological Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6225797/
https://ncbi.nlm.nih.gov/pubmed/30076156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2018-213502
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky